UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
UNITY Biotechnology (NASDAQ: UBX) has announced a virtual investor event scheduled for March 24, 2025, at 8:00 AM ET to discuss important data from their Phase 2b ASPIRE study. The event will present 24- and 36-week results evaluating UBX1325 in patients with Diabetic Macular Edema (DME).
The presentation will feature Dr. Robert Bhisitkul, a key opinion leader from UCSF School of Medicine, alongside company management. UBX1325, characterized as a potent BCL-xL inhibitor with senolytic mechanism of action, is being developed to potentially improve long-term visual outcomes. The event will conclude with a live Q&A session.
UNITY Biotechnology (NASDAQ: UBX) ha annunciato un evento virtuale per investitori programmato per il 24 marzo 2025, alle 8:00 AM ET, per discutere dati importanti del loro studio di Fase 2b ASPIRE. L'evento presenterà i risultati a 24 e 36 settimane che valutano UBX1325 in pazienti con Edema Maculare Diabetico (DME).
La presentazione vedrà la partecipazione del Dr. Robert Bhisitkul, un leader di opinione chiave della UCSF School of Medicine, insieme alla direzione dell'azienda. UBX1325, caratterizzato come un potente inibitore di BCL-xL con un meccanismo d'azione senolitico, è in fase di sviluppo per migliorare potenzialmente i risultati visivi a lungo termine. L'evento si concluderà con una sessione di domande e risposte dal vivo.
UNITY Biotechnology (NASDAQ: UBX) ha anunciado un evento virtual para inversores programado para el 24 de marzo de 2025, a las 8:00 AM ET, para discutir datos importantes de su estudio de Fase 2b ASPIRE. El evento presentará los resultados a 24 y 36 semanas que evalúan UBX1325 en pacientes con Edema Macular Diabético (DME).
La presentación contará con la participación del Dr. Robert Bhisitkul, un líder de opinión clave de la UCSF School of Medicine, junto con la dirección de la empresa. UBX1325, caracterizado como un potente inhibidor de BCL-xL con un mecanismo de acción senolítico, se está desarrollando para potencialmente mejorar los resultados visuales a largo plazo. El evento concluirá con una sesión de preguntas y respuestas en vivo.
UNITY Biotechnology (NASDAQ: UBX)는 2025년 3월 24일 오전 8시(ET)에 예정된 가상 투자자 이벤트를 발표했습니다. 이 이벤트에서는 2b상 ASPIRE 연구의 중요한 데이터를 논의할 예정입니다. 이 이벤트에서는 24주 및 36주 결과를 발표하여 당뇨병성 황반부종(DME) 환자에서 UBX1325를 평가합니다.
발표에는 UCSF 의과대학의 핵심 의견 리더인 Dr. Robert Bhisitkul가 회사 경영진과 함께 참여합니다. UBX1325는 강력한 BCL-xL 억제제로, 세놀리틱 작용 메커니즘을 가지고 있으며, 장기적인 시각 결과를 개선하기 위해 개발되고 있습니다. 이벤트는 라이브 Q&A 세션으로 마무리됩니다.
UNITY Biotechnology (NASDAQ: UBX) a annoncé un événement virtuel pour les investisseurs prévu le 24 mars 2025 à 8h00 ET pour discuter de données importantes de leur étude de Phase 2b ASPIRE. L'événement présentera les résultats à 24 et 36 semaines évaluant UBX1325 chez des patients atteints de œdème maculaire diabétique (DME).
La présentation mettra en vedette Dr. Robert Bhisitkul, un leader d'opinion clé de la UCSF School of Medicine, aux côtés de la direction de l'entreprise. UBX1325, caractérisé comme un puissant inhibiteur de BCL-xL avec un mécanisme d'action sénolytique, est en cours de développement pour améliorer potentiellement les résultats visuels à long terme. L'événement se conclura par une session de questions-réponses en direct.
UNITY Biotechnology (NASDAQ: UBX) hat ein virtuelles Investoren-Event für den 24. März 2025 um 8:00 Uhr ET angekündigt, um wichtige Daten aus ihrer Phase 2b ASPIRE-Studie zu diskutieren. Bei der Veranstaltung werden die Ergebnisse nach 24 und 36 Wochen präsentiert, die UBX1325 bei Patienten mit Diabetischem Makulaödem (DME) bewerten.
Die Präsentation wird Dr. Robert Bhisitkul, einen führenden Meinungsführer der UCSF School of Medicine, zusammen mit dem Management des Unternehmens umfassen. UBX1325, das als potenter BCL-xL-Inhibitor mit senolytischem Wirkmechanismus charakterisiert ist, wird entwickelt, um potenziell die langfristigen visuellen Ergebnisse zu verbessern. Die Veranstaltung endet mit einer Live-Q&A-Session.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here.
The event will feature prominent ophthalmology key opinion leader (KOL) Robert Bhisitkul, MD, PhD from the UCSF School of Medicine, who will join company management to review 24- and 36-week results from the Phase 2b ASPIRE study evaluating the safety and efficacy of UBX1325 in patients with DME. UBX1325 is a potent BCL-xL inhibitor that acts via a senolytic mechanism of action, with the potential to improve long-term visual outcomes.
A live question and answer session will follow the formal presentations.
About UBX1325
UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of BCL-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting BCL-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with retinal disease.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Media Contact
Inizio Evoke Comms
Katherine Smith
katherine.smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
What are the key findings from UBX1325's Phase 2b ASPIRE trial for DME treatment?
How does UBX1325 work in treating Diabetic Macular Edema?
When will UNITY Biotechnology (UBX) present its ASPIRE study results?
Who will present at the UBX virtual investor event for ASPIRE study results?
